6838 — Formosa Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- TWD5.39bn
- TWD3.82bn
- TWD143.36m
Annual income statement for Formosa Pharmaceuticals, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 28.5 | 1.31 | 31.2 | 143 |
| Cost of Revenue | |||||
| Gross Profit | — | 28.3 | 0.333 | 27.3 | 119 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 234 | 409 | 383 | 314 | 319 |
| Operating Profit | -234 | -380 | -382 | -283 | -176 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -220 | -398 | -407 | -300 | -180 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -220 | -401 | -406 | -322 | -201 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -220 | -401 | -406 | -322 | -201 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -220 | -401 | -406 | -322 | -201 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.12 | -4.15 | -3.86 | -2.59 | -1.43 |
| Dividends per Share |